Back to Authors

Barkmeier, Andrew J.

https://orcid.org/0000-0002-2666-3828

Mayo Clinic

Mayo Clinic

Citations 21

Regression of Serous Macular Detachment Due to Peripheral Exudative Hemorrhagic Chorioretinopathy following Intravitreal Bevacizumab
Kadikoy, Hüseyin, Holz, Eric R. , Carvounis, Petros , Barkmeier, Andrew J.

European Journal of Ophthalmology | January 14, 2011 | Volume: 21 | Issue: 4 | Pages: 506-508

10.5301/ejo.2011.6246 Get It

Purpose TO describe a case of exudative macular detachment secondary to peripheral exudative chorioretinopathy with a favorable anatomic and visual outcome following treatment with intravitreal bevacizumab. Methods The medical records of a patient with peripheral exudative chorioretinopathy were reviewed. Results Macular reattachment was achieved with a corresponding visual acuity improvement that was maintained over an uncomplicated 17-month clinical course. Conclusions Bevacizumab may be an effective treatment option for exudative macular detachment secondary to peripheral exudative hemorrhagic chorioretinopathy.